Cite
IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
MLA
Gu, Aiqin, et al. “IL13Rα2-Targeted Third-Generation CAR-T Cells with CD28 Transmembrane Domain Mediate the Best Anti-Glioblastoma Efficacy.” Cancer Immunology, Immunotherapy, vol. 72, no. 7, July 2023, pp. 2393–403. EBSCOhost, https://doi.org/10.1007/s00262-023-03423-5.
APA
Gu, A., Bai, Y., Zhang, C., Xu, C., An, Z., Zhang, Y., Zhong, S. H., Hu, Y., & Zhong, X. (2023). IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy. Cancer Immunology, Immunotherapy, 72(7), 2393–2403. https://doi.org/10.1007/s00262-023-03423-5
Chicago
Gu, Aiqin, Yue Bai, Can Zhang, Chang Xu, Zhijing An, Ying Zhang, Steven H. Zhong, Yi Hu, and Xiaosong Zhong. 2023. “IL13Rα2-Targeted Third-Generation CAR-T Cells with CD28 Transmembrane Domain Mediate the Best Anti-Glioblastoma Efficacy.” Cancer Immunology, Immunotherapy 72 (7): 2393–2403. doi:10.1007/s00262-023-03423-5.